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The  human  immunodeﬁciency  virus  type-1  (HIV-1)  vaccine  candidate  F4/AS01  has  previously  been
shown  to induce  potent  and  persistent  polyfunctional  CD4+ T-cell  responses  in HIV-1-seronegative  vol-
unteers.  This  placebo-controlled  study  evaluated  two doses  of  F4/AS01  1-month  apart  in antiretroviral
treatment  (ART)-experienced  and ART-naïve  HIV-1-infected  subjects  (1:1  randomisation  in each  cohort).
Safety,  HIV-1-speciﬁc  CD4+ and  CD8+ T-cell  responses,  absolute  CD4+ T-cell  counts  and  HIV-1 viral load
were  monitored  for  12  months  post-vaccination.  Reactogenicity  was  clinically  acceptable  and  no  vaccine-
related  serious  adverse  events  were  reported.  The  frequency  of  HIV-1-speciﬁc  CD4+ T-cells  2 weeks
post-dose  2 was  signiﬁcantly  higher  in  the  vaccine  group  than in the  placebo  group  in both  cohorts
(p  <  0.05).  Vaccine-induced  HIV-1-speciﬁc  CD4+ T-cells  exhibited  a polyfunctional  phenotype,  expressing
at  least  CD40L  and  IL-2. No increase  in HIV-1-speciﬁc  CD8+ T-cells  or change  in  CD8+ T-cell  activation
marker  expression  proﬁle  was  detected.  Absolute  CD4+ T-cell  counts  were  variable  over  time  in both
cohorts.  Viral  load  remained  suppressed  in  ART-experienced  subjects.  In  ART-naïve  subjects,  a transient
reduction  in  viral  load from  baseline  was  observed  2 weeks  after  the  second  F4/AS01  dose,  which  was
+concurrent  with  a higher  frequency  of  HIV-1-speciﬁc  CD4 T-cells  expressing  at least  IL-2 in  this  cohort.
In  conclusion,  F4/AS01  showe
polyfunctional  HIV-1-speciﬁc  
ﬁndings  support  further  clinica
in  individuals  with  HIV-1  infec
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. Introduction
There is considerable interest in development of therapeutic
accines to improve control of HIV-1 viral load via induction of
trong and persistent cellular immune responses. Evidence of HIV-
-infected subjects with long-term nonprogression (LTNP) in the
bsence of ART suggests that immune control of HIV-1 infection is
ossible [1,2]. Polyfunctional and proliferation-competent HIV-1-
peciﬁc CD4+ T-cells are critical in the immune control of HIV-1,
eing required for the induction and maintenance of functional
D8+ T-cells [3–6]. Indeed, the loss of HIV-1-speciﬁc CD8+ T-cell
roliferation after acute HIV-1 infection can be restored by vaccine-
nduced HIV-1-speciﬁc CD4+ T-cells that produce IL-2 in vitro and
n vivo [7]. Such ﬁndings suggest that therapeutic vaccines induc-
ng strong CD4+ T-cell responses may  promote reconstitution of
D8+ T-cell responses, reduce HIV-1 viral load and delay disease
rogression.
The HIV-1 vaccine candidate F4/AS01 has previously been
hown to induce potent and persistent polyfunctional cross-
eactive CD4+ T-cell responses in healthy HIV-1-seronegative
olunteers [8]. This study evaluated the safety and immunogenic-
ty of F4/AS01 in HIV-1-infected ART-experienced and ART-naïve
ndividuals.
. Methods
.1. Study vaccine
F4/AS01  (GlaxoSmithKline Vaccines, Rixensart, Belgium) con-
ains 10 g recombinant fusion protein F4 adjuvanted with AS01B
8]. F4 is produced in Escherichia coli and comprises 4 full-length
IV-1 clade B antigens: p24 (BH10), RT (HXB2), Nef (Bru-Lai) and
17 (BH10). AS01B is an Adjuvant System containing 50 g 3-O-
esacyl-4′-monophosphoryl lipid A (MPL), 50 g QS-21 (Quillaja
aponaria Molina, fraction 21; Antigenics Inc., a wholly owned sub-
idiary of Agenus Inc., Lexington MA,  USA) and liposomes.
.2.  Study design and participants
This  Phase I, randomised, observer-blind, placebo-controlled
rial was conducted at 6 centres in Germany in accordance with
he Declaration of Helsinki and Good Clinical Practice guidelines [9].
he study was approved by the local independent ethics committee
nd the German regulatory authority. All subjects provided written
nformed consent. The primary objective was to evaluate the reac-
ogenicity and safety of the vaccine. Secondary objectives included
ssessment of HIV-1-speciﬁc CD4+ T-cell responses, CD4+ T-cell
ount and HIV-1 viral load. HIV-1-speciﬁc CD8+ T-cell responses
nd humoral immune responses to F4 and its component antigens
ere assessed as exploratory objectives.
HIV-1 infected adults aged 18–55 years with stable, asymp-
omatic HIV-1 infection and CD4+ T-cell count ≥450 cells/mm3
ere eligible. ART-experienced subjects must have been stable on
RT for ≥1 year with an undetectable viral load (<50 copies/ml
IV-1 RNA) on two occasions at least 3 months apart during the
 months prior to enrolment. ART-naïve subjects had to have a
iral load of 5000–80,000 copies/ml at screening. Other standard
ligibility criteria were used for enrolment [9]. ART-naïve subjects
ere only enrolled after a planned review of safety data from the
RT-experienced cohort.
In each cohort, subjects were randomised (1:1) to receive twooses of F4/AS01 or 0.9% saline (placebo) intramuscularly (deltoid,
on-dominant arm) 1-month apart. Randomisation was performed
sing a central internet-based system. In ART-naïve subjects, ran-
omisation took into account viral load at screening (<40,000 or (2014) 2657–2665
≥40,000 copies/ml). Subjects were followed for 12 months post-
dose 1. Blood samples for assessment of cell-mediated immune
and antibody responses were obtained before vaccination, 2 weeks
post-dose 2 and at month 4 and 12. CD4+ T-cell count, viral load and
haematology/biochemistry were monitored throughout the study
period. All laboratory assays were performed blinded.
2.3.  Safety
Local (injection site pain, redness, swelling) and general (fever,
fatigue, headache, sweating, myalgia, gastrointestinal symptoms)
solicited adverse events (AEs) were predeﬁned and recorded on
diary cards for 7 days post-vaccination. All other unsolicited AEs
were recorded for 30 days post-vaccination. Severity of AEs was
assessed using the National Institute of Allergy and Infectious Dis-
eases Division of AIDS (DAIDS) AE grading system [10]. Serious
adverse events (SAEs) and the following pre-deﬁned HIV-1-related
AEs were assessed throughout the study period: ≥25% reduc-
tion in CD4+ T-cell count from baseline; detectable viral load
(≥50 copies/ml HIV-1 RNA) in ART-experienced subjects or ≥0.5
log increase in viral load in ART-naïve subjects; change or initiation
of ART; and abnormal biochemistry and/or haematology (deﬁned
as ≥1 on the DAIDS scale). All solicited local AEs were considered
causally related to vaccination. The potential relationship of all
other AEs to vaccination was assessed by the investigator. Safety
data were reviewed by an independent data monitoring committee.
2.4. HIV-1 viral load
HIV-1  viral load was tested with the Roche COBAS® Amplicor
HIV-1 Monitor Test v1.5 in ART-experienced subjects and the Roche
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test v1.0 in ART-naïve
subjects.
2.5. CD4+ T-cell counts
CD4+ T-cell counts were initially performed using the BD
MultitestTM IMK  kit (a four-colour assay) (BD Biosciences) and read
using a BD FACSCaliburTM ﬂow cytometer. During the study, the
method was upgraded to use the BD MultitestTM 6-colour TBNK
reagent and the BD FACSCantoTM II system after an extensive vali-
dation process.
2.6.  Immune responses
HIV-1-speciﬁc CD4+ and CD8+ T-cell responses were evaluated
by intracellular cytokine staining (ICS) following in vitro stim-
ulation with p17, p24, RT and Nef peptide pools to assess the
expression of interleukin-2 (IL-2), interferon- (IFN-), tumour
necrosis factor- (TNF-) and CD40-ligand (CD40L) using periph-
eral blood mononuclear cells (PBMCs) isolated from venous blood
[8].
HIV-1-speciﬁc CD4+ T-cell responses were expressed as the fre-
quency of CD40L+CD4+ T-cells expressing at least IL-2, the cytokine
co-expression proﬁle and the percentage of responders after in vitro
stimulation to each individual antigen and to at least 1, 2, 3 or 4
antigens. This was  a pre-deﬁned endpoint based on results of a
previous study of F4/AS01 in healthy HIV-1-seronegative volun-
teers, in which almost all vaccine-induced CD4+ T-cells were found
to express at least CD40L and IL2 [8]. If cytokine secretion was
undetectable pre-vaccination, a subject was  considered a respon-
der if the proportion of CD40L+CD4+ T-cells expressing at least IL-2
was ≥0.03% (assay cut-off). In subjects with detectable cytokine
secretion pre-vaccination, response was deﬁned as a greater than
2-fold increase in CD40L+CD4+ T-cells expressing at least IL-2 from
baseline.
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HIV-1-speciﬁc CD8+ T-cell responses were expressed as the fre-
uency of CD8+ T-cells expressing at least 1 cytokine (IL-2, TNF-, or
FN-). Additional exploratory analyses were performed in the ART-
xperienced cohort. PBMCs were stimulated in vitro either with
eptide pools spanning the F4 antigen or with a selection of 6 9-mer
eptides in Human Leucocyte Antigen (HLA) A*02-positive patients
RT33–41, RT127–135, RT179–187, RT309–317, p1777–85, p2419–27; HXB2
train) [11,12]. Following the same procedure as described above,
ells were then stained with either a ﬁrst panel of anti-CD8, CD3,
-1BB, MIP-1, IL-2, IFN antibodies and a pool of 6 tetramers (spe-
iﬁc to the 6 peptides) or with a second panel of anti-CD3, CD8,
-1BB, IFN, perforin and granzyme B antibodies and the pool of
 tetramers. Ex vivo staining was also performed to analyse PD-1
xpression, as well as activation markers such as CD38, HLA DR,
CR5 and Ki-67 on the total CD8+ T-cells or tetramer+ CD8+ T-cells.
Immunoglobulin G (IgG) antibody titres to F4, p17, p24, RT
nd Nef were analysed using standard in-house enzyme-linked
mmunosorbent assays (ELISA) as previously described [8]. The cut-
ff for seropositivity was ≥187 mELISA units (mEU)/ml for p17,
119 mEU/ml for p24, ≥125 mEU/ml for RT, ≥232 mEU/ml for Nef
nd ≥42 mEU/ml for F4.
In ART-naïve subjects, HLA typing (HLA-A, B, C and DRB1) was
erformed with the LABType® SSO PCR/LABType® SSO analysis
oftware (One-Lambda).
.7.  Statistical analysis
The  target sample size was 22 ART-experienced and 22 ART-
aïve subjects. Analysis of safety and reactogenicity was  performed
n the total vaccinated cohort (TVC). The number and percentage of
ubjects reporting AEs were calculated with exact 95% conﬁdence
ntervals (CI). Change in mean CD4+ T-cell count and median viral
oad from baseline were summarised for each treatment group in
ach cohort at all time-points.
Analysis  of immunogenicity was performed on the according-
o-protocol (ATP) cohort. Results were summarised within each
roup at each time-point using descriptive statistics for continuous
ariables and percentages (with 95% CI) for categorical variables.
he F4-speciﬁc CD4+ T-cell response was estimated from the sum
f the speciﬁc CD4+ T-cell frequencies in response to each individual
ntigen.
Exploratory comparisons between groups were derived for viral
oad, CD4+ T-cell count and CD4+ T-cell response, based on analy-
is of covariance (ANCOVA) models with the baseline as covariate
or all time-points, except baseline where no adjustment was per-
ormed (ANOVA), using the arithmetic scale for CD4+ cell count and
he log scale for viral load and CD4+ T-cell response. No adjustments
ere made for multiplicity.
.  Results
.1. Demographics
In  all, 33 ART-experienced and 43 ART-naïve subjects were
creened for study participation (Fig. S1). Nine and 10 ART-
xperienced and 11 and 11 ART-naïve subjects received the ﬁrst
ose of vaccine or placebo, respectively, and were included in the
afety analyses. Baseline demographic or clinical characteristics
ere broadly similar between the vaccine and placebo groups in
oth cohorts (Table 1).
Supplementary  material related to this article can be found,
n the online version, at http://dx.doi.org/10.1016/j.vaccine.2013.
0.030.
Nine and 8 ART-experienced and 5 and 7 ART-naïve subjects
n the vaccine and placebo groups, respectively, were eligible for (2014) 2657–2665 2659
inclusion in the ATP cohorts for analysis of immunogenicity. Rea-
sons for exclusion from the ATP immunogenicity analysis included
essential data on CD4+ T-cell responses missing, concomitant infec-
tion and lack of compliance with the vaccination schedule.
3.2.  Safety and reactogenicity
Reactogenicity during the 7-day post-vaccination period is
shown in Table 2. Pain was  the only solicited local AE reported by
more than 1 subject in any group after either dose and was more
common in the F4/AS01 groups than in the placebo groups. The
most common solicited general AEs were fatigue and headache
in ART-experienced subjects and fatigue, headache, myalgia and
sweating in ART-naïve subjects. No solicited grade 3/4 AEs were
reported by more than 1 subject in any group. All solicited local
AEs and most solicited general AEs were considered related to vac-
cination by the investigator.
The  percentage of subjects reporting unsolicited AEs during
the 30-day post-vaccination period is shown in Table S1. After
the 30-day post-vaccination period, 5 and 4 subjects in the ART-
experienced vaccine and placebo groups and 9 and 10 subjects in
the ART-naïve vaccine and placebo experienced at least one unso-
licited AE requiring medical attention. All unsolicited AEs were
heterogeneous in nature and no apparent trends were noted. No
grade 3/4 laboratory parameters were reported in the vaccine group
in either cohort, with the exception of grade 3 bilirubin in one
ART-experienced subject which was related to atazanavir use.
Supplementary material related to this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.vaccine.2013.
10.030.
No SAEs were reported in the ART-experienced group. SAEs were
reported by 3 ART-naïve vaccine recipients (injury of the rectum,
hepatitis B and cholelithiasis) and 3 ART-naïve placebo recipients
(ophthalmic herpes zoster with bacterial superinfection, personal-
ity disorder with pyelonephritis and pyomyositis). All SAEs were
considered unrelated to vaccination and resolved without seque-
lae. HIV-1-related AEs were observed in 6 subjects in each of the
ART-experienced groups and 8 and 11 subjects in the ART-naïve
vaccine and placebo groups, respectively (Table 3).
3.3.  CD4+ T-cell responses
Pre-existing F4-speciﬁc CD40L+CD4+ T-cells expressing at
least IL-2 were detected at a low frequency in both groups
in ART-experienced and ART-naïve subjects prior to vaccina-
tion. Exploratory analyses showed the frequency of F4-speciﬁc
CD40L+CD4+ T-cells expressing at least IL-2 to be signiﬁcantly
higher (p < 0.05) in the vaccine group than in the placebo group two
weeks post-dose 2 in both cohorts (Fig. 1). In ART-experienced sub-
jects, this difference between the vaccine and the placebo groups
remained signiﬁcant up to month 4 (p < 0.05), and F4-speciﬁc CD4+
T-cell responses were still detected in vaccine recipients at month
12. Almost all vaccinees developed a CD4+ T-cell response two
weeks post-dose 2 to at least one of the four antigens, with highest
response rates seen against the RT and p24 antigens (Table S2).
Supplementary material related to this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.vaccine.2013.
10.030.
Vaccine-induced CD4+ T-cells exhibited a polyfunctional pheno-
type (Fig. S2). In ART-experienced subjects, approximately 75% of
F4-speciﬁc CD40L+CD4+ T-cells secreted ≥2 cytokines and approx-
imately 35% secreted ≥3 cytokines and this cytokine coexpression
proﬁle was maintained until month 12. A similar trend was
observed in ART-naïve subjects; however, results in this cohort
must be interpreted with caution due to the low frequency of F4-
speciﬁc CD4+ T-cells induced (data not shown).
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Fig. 1. Percentage of F4-speciﬁc CD40L+CD4+ T-cells expressing at least IL-2 (ATP cohort for immunogenicity); (a) overall response to F4 in ART-experienced and ART-naïve
subjects; (b) response to speciﬁc antigens in ART-experienced subjects; and (c) response to speciﬁc antigens in ART-naïve subjects. P-values are based on 95% CI for the
geometric mean ratio F4/AS01 over placebo derived by ANCOVA model adjusted for baseline (except at the pre-vaccination timepoint where no adjustment was  performed
[ANOVA]).
T. Harrer et al. / Vaccine 32 (2014) 2657–2665 2661
Table  1
Baseline demography and clinical characteristics (TVC).
Characteristic ART-experienced ART-naïve
F4/AS01 (N = 9) Placebo (N = 10) F4/AS01 (N = 11) Placebo (N = 11)
Age (years)
Mean 44.3 43.4 39.9 35.4
Range  40–48 28–50 27–54 22–48
Gender  (n)
Male/Female 8/1 10/0 11/0 10/1
Ethnicity  (Race)
Caucasian 9 9 9 11
Other  0 1 2 0
Time  from diagnosis to dose 1 (years)
Median 11 7 2 3
Range  8–22 2–21  0–10 0–8
Mean  13.1 8.1 3.6 2.9
CD4  nadir (cells/mm3)
Median 249 209.5 601 563
Range  142–391 103–472 345–873 440–613
Mean  251.3 242.0 569.7 539.8
Time  from CD4 nadir to dose 1 (years)
Median 8 5.5 1 0
Range  2–12 1–10 0–5 0–2
Mean  7.9 5.3 1.4 0.4
Viral  load (log10 copies/ml)
Median b b 4.32 4.12
Range b b 3.78–4.84 3.36–4.81
Mean b b 4.32 4.14
HIV  clade (n)
Clade  B 1 2 7 3
Unknown  8 8 4 8
ART  treatment (n)
NRTI(s)  + NNRTI only 6 4 – –
NRTI(s)  + PI(s) only 3 4 – –
Triple  NRTI(s) only 0 1 – –
Othera 0 1 – –
N, number of subjects vaccinated; n, number of subjects in the given category; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-
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cucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
a 2PIs, integrase inhibitor and CCR5 receptor antagonist.
b All ART-experienced subjects had an undetectable viral load at baseline (<50 co
Supplementary material related to this article can be found,
n the online version, at http://dx.doi.org/10.1016/j.vaccine.2013.
0.030.
.4. CD8+ T-cell responses
High levels of HIV-1-speciﬁc CD8+ T-cells expressing mainly
FN- were detected at baseline in both cohorts. Irrespective of the
arker tested or the stimulatory peptide pools used, no increase in
IV-1-speciﬁc CD8+ T-cell frequency or change in the expression
roﬁle of CD8+ T-cell activation markers was detected following
accination in either cohort (data not shown).
.5. Humoral immune responses
Pre-existing IgG antibodies against the F4 fusion protein and
gainst all four of the individual vaccine antigens were detected
n both cohorts. Vaccination increased antibody levels against
he F4 fusion protein and all individual vaccine antigens in ART-
xperienced subjects, but not in ART-naïve subjects who had higher
re-vaccination titres compared to ART-experienced subjects (Fig.
3).
Supplementary material related to this article can be found,
n the online version, at http://dx.doi.org/10.1016/j.vaccine.2013.
0.030..6. CD4+ T-cell count and viral load
Absolute CD4+ T-cell counts were variable over time in both
ohorts. Ad hoc comparisons of change from baseline detected nol HIV-1 RNA).
signiﬁcant differences between vaccine and placebo groups at any
time-point in either cohort (data not shown).
Except for two minor blips in the vaccine group and one minor
blip in the placebo group, viral load remained suppressed in both
groups of ART-experienced subjects over the 12 months of follow-
up. In ART-naïve subjects, ad hoc comparisons of change in viral
load from baseline indicated a signiﬁcant difference in favour of
the vaccine group, in which a transient reduction in viral load from
baseline was observed two  weeks post-dose 2 (p < 0.05) (Fig. 2). This
difference was sustained over the 12 months of follow-up, but was
only statistically signiﬁcant at two  weeks post-dose 2. In ART-naïve
subjects, a correlation was  observed between the reduction in viral
load from baseline and the frequency of CD4+ T-cells expressing at
least IL-2 at two weeks post-dose 2 (p = 0.0054) (Fig. 3).
3.7. Analysis of the inﬂuence of HLA-I alleles on vaccine response
No  association was  observed between protective HLA-I alleles
(B*27, B*5801) or unfavourable HLA-I alleles (B*35 types), haplo-
types and randomisation (placebo vs. vaccine), change in viral load
or change in CD4+ T-cell counts (data not shown). There were no
patients carrying the protective HLA-I alleles B*57 and B*5802.
4.  DiscussionNumerous different approaches have been studied for poten-
tial use as therapeutic vaccines against HIV-1 [13,14]. However,
none of these approaches have yielded durable improvements
in immune control of HIV-1 infection. Strong, polyfunctional and
2662 T. Harrer et al. / Vaccine 32 (2014) 2657–2665
Table 2
Percentage of subjects reporting solicited local or general adverse events during the 7-day post-vaccination period (TVC). Solicited local AEs (pain, redness, swelling at site of
injection)  and general AEs (fever, fatigue, headache, sweating, myalgia, anorexia, diarrhoea, nausea, vomiting, abdominal pain) were predeﬁned and recorded on diary cards
for  7 days after each vaccination.
ART-experienced subjects ART-naïve subjects
F4/AS01 (N = 9) Placebo (N = 10) F4/AS01 (N = 11) Placebo (N = 11)
n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI)
Paina
Any 7 77.8 (40.0–97.2) 3 30.0 (6.7–65.2) 8 72.7 (39.0–94.0) 3 27.3 (6.0–61.0)
Grade  3/4b 1 11.1 (0.3–48.2) 0 0 (0.0–30.8) 0 0 (0.0–28.5) 0 0 (0.0–28.5)
Rednessa
Any 1 11.1 (0.3–48.2) 0 0 (0.0–30.8) 0 0 (0.0–28.5) 0 0 (0.0–28.5)
>50  mmc 1 11.1 (0.3–48.2) 0 0 (0.0–30.8) 0 0 (0.0–28.5) 0 0 (0.0–28.5)
Swellinga
Any 1 11.1 (0.3–48.2) 0 0 (0.0–30.8) 1 9.1 (0.2–41.3) 0 0 (0.0–28.5)
>50  mmc 1 11.1 (0.3–48.2) 0 0 (0.0–30.8) 1 9.1 (0.2–41.3) 0 0 (0.0–28.5)
Fever
Any  (≥37.7 ◦C) 2 22.2 (2.8–60.0) 1 10.0 (0.3–44.5) 1 9.1 (0.2–41.3) 1 9.1 (0.2–41.3)
Grade  3/4b 0 0 (0.0–33.6) 0 0 (0.0–30.8) 0 0 (0.0–28.5) 0 0 (0.0–28.5)
Related  2 22.2 (2.8–60.0) 0 0 (0.0–30.8) 1 9.1 (0.2–41.3) 1 9.1 (0.2–41.3)
Fatigue
Any  2 22.2 (2.8–60.0) 6 60.0 (22.6–87.8) 2 18.2 (2.3–51.8) 6 54.5 (23.4–83.3)
Grade  3/4b 0 0 (0.0–33.6) 0 0 (0.0–30.8) 0 0 (0.0–28.5) 1 9.1 (0.2–41.3)
Related  2 22.2 (2.8–60.0) 5 50.0 (18.7–81.3) 2 18.2 (2.3–51.8) 4 36.4 (10.9–69.2)
Headache
Any  3 33.3 (7.5–70.1) 4 40.0 (12.2–73.8) 2 18.2 (2.3–51.8) 3 27.3 (6.0–61.0)
Grade  3/4b 1 11.1 (0.3–48.2) 0 0 (0.0–30.8) 0 0 (0.0–28.5) 1 9.1 (0.2–41.3)
Related  2 22.2 (2.8–60.0) 2 20.0 (2.5–55.6) 2 18.2 (2.3–51.8) 2 18.2 (2.3–51.8)
Sweating
Any  2 22.2 (2.8–60.0) 4 40.0 (12.2–73.8) 3 27.3 (6.0–61.0) 4 36.4 (10.9–69.2)
Grade  3/4b 0 0 (0.0–33.6) 0 0 (0.0–30.8) 0 0 (0.0–28.5) 1 9.1 (0.2–41.3)
Related  2 22.2 (2.8–60.0) 3 30.0 (6.7–65.2) 2 18.2 (2.3–51.8) 3 27.3 (6.0–61.0)
Myalgia
Any  2 22.2 (2.8–60.0) 3 30.0 (6.7–65.2) 3 27.3 (6.0–61.0) 4 36.4 (10.9–69.2)
Grade  3/4b 0 0 (0.0–33.6) 0 0 (0.0–30.8) 0 0 (0.0–28.5) 0 0 (0.0–28.5)
Related  1 11.1 (0.3–48.2) 2 20.0 (2.5–55.6) 3 27.3 (6.0–61.0) 3 27.3 (6.0–61.0)
Abdominal  pain
Any  0 0 (0.0–33.6) 0 0 (0.0–30.8) 1 9.1 (0.2–41.3) 1 9.1 (0.2–41.3)
Grade  3/4b 0 0 (0.0–33.6) 0 0 (0.0–30.8) 1 9.1 (0.2–41.3) 0 0 (0.0–28.5)
Related  0 0 (0.0–33.6) 0 0 (0.0–30.8) 0 0 (0.0–28.5) 0 0 (0.0–28.5)
Anorexia
Any  0 0 (0.0–33.6) 1 10.0 (0.3–44.5) 1 9.1 (0.2–41.3) 3 27.3 (6.0–61.0)
Grade  3/4b 0 0 (0.0–33.6) 0 0 (0.0–30.8) 0 0 (0.0–28.5) 0 0 (0.0–28.5)
Related  0 0 (0.0–33.6) 1 10.0 (0.3–44.5) 1 9.1 (0.2–41.3) 2 18.2 (2.3–51.8)
Diarrhoea
Any  0 0 (0.0–33.6) 3 30.0 (6.7–65.2) 0 0 (0.0–28.5) 5 45.5 (16.7–76.6)
Grade  3/4b 0 0 (0.0–33.6) 0 0 (0.0–30.8) 0 0 (0.0–28.5) 1 9.1 (0.2–41.3)
Related  0 0 (0.0–33.6) 2 20.0 (2.5–55.6) 0 0 (0.0–28.5) 3 27.3 (6.0–61.0)
Nausea
Any  2 22.2 (2.8–60.0) 2 20.0 (2.5–55.6) 0 0 (0.0–28.5) 3 27.3 (6.0–61.0)
Grade  3/4b 1 11.1 (0.3–48.2) 0 0 (0.0–30.8) 0 0 (0.0–28.5) 0 0 (0.0–28.5)
Related  2 22.2 (2.8–60.0) 2 20.0 (2.5–55.6) 0 0 (0.0–28.5) 1 9.1 (0.2–41.3)
Vomiting
Any  0 0 (0.0–33.6) 1 10.0 (0.3–44.5) 0 0 (0.0–28.5) 2 18.2 (2.3–51.8)
Grade  3/4b 0 0 (0.0–33.6) 0 0 (0.0–30.8) 0 0 (0.0–28.5) 0 0 (0.0–28.5)
Related  0 0 (0.0–33.6) 1 10.0 (0.3–44.5) 0 0 (0.0–28.5) 1 9.1 (0.2–41.3)
N, number of subjects who received at least one dose; n/%, number/percentage of subjects reporting AE; 95% CI, exact 95% conﬁdence intervals.
a All solicited local AEs were considered related to vaccination; relationship of general solicited AEs to vaccination was assessed by the investigator.
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ther  AEs causing inability to perform usual social and functional activities.
c Diameter >50 mm = DAIDS grade 1.
ross-reactive vaccine-induced T-cell responses are likely to be
equired to control HIV-1 replication. A potent approach to promote
D4+ T-cell responses is the use of adjuvanted protein vaccines
15,16]. A previous HIV-1 vaccine candidate comprising gp120 and
 Nef-Tat fusion protein formulated with AS01 or another similar
djuvant System elicited strong CD4+ T-cell responses in healthy
IV-1-seronegative subjects [17,18] and in HIV-1-infected sub-
ects receiving ART [19]. F4/AS01 has previously been shown to
nduce strong polyfunctional, broadly reactive and persistent CD4+
-cell responses in healthy HIV-1-seronegative volunteers [8]. The
resent study assessed the safety and immunogenicity of F4/AS01
n ART-experienced and ART-naïve HIV-1-infected individuals.onal activities, fever ≥39.4 C, nausea resulting in minimal oral intake for >48 h, all
We found F4/AS01 to have an acceptable safety proﬁle in
ART-experienced and ART-naïve subjects, with reactogenicity
lower than previously observed in healthy HIV-1-seronegative
volunteers [8]. The clinically acceptable safety proﬁle of F4/AS01
observed in this study is consistent with clinical experience with
AS01 in combination with other antigens [20–22].
F4/AS01 elicited higher HIV-1-speciﬁc CD4+ T-cell responses
in both ART-experienced and ART-naïve subjects compared
to placebo, with no aggravation of HIV-1 infection. Almost all
vaccinees developed a CD4+ T-cell response to at least one
antigen, with strongest responses directed against RT and p24.
CD4+ T-cell responses appeared higher and more persistent in
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Table  3
Percentage of subjects reporting pre-deﬁned HIV-1-related adverse events up to Month 12 (TVC).
Categories ART-experienced subjects ART-naïve subjects
F4/AS01 (N = 9) Placebo (N = 10) F4/AS01 (N = 11) Placebo (N = 11)
n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI)
HIV-1-related AE (any category) 6 66.7 (29.9–92.5) 6 60.0 (26.2–87.8) 8 72.7 (39.0–94.0) 11 100 (71.5–100)
Decrease  in CD4+ count ≥25% versus baseline 2 22.2 (2.8–60.0) 3 30.0 (6.7–65.2) 5 45.5 (16.7–76.6) 4 36.4 (10.9–69.2)
Biochemistry  parameter grading ≥1 (per DAIDS) 5 55.6 (21.2–86.3) 6 60.0 (26.2–87.8) 3 27.3 (6.0–61.0) 8 72.7 (39.0–94.0)
Detectable  viral load/increase in viral loada 3 33.3 (7.5–70.1) 2 20.0 (2.5–55.6) 3 27.3 (6.0–61.0) 7 63.6 (30.8–89.1)
Change  in ART/ART initiation 1b 11.1 (0.3–48.2) 1c 10.0 (0.3–44.5) 0 0.0 (0.0–28.5) 1d 9.1 (0.2–41.3)
N, number of subjects who received at least one dose; n/%, number/percentage of subjects reporting at least one AE; 95% CI, exact 95% conﬁdence intervals.
a Detectable viral load (≥50 copies/ml HIV-1 RNA) assessed for ART-experienced cohort and increase in viral load (increase of at least 0.5 log post-vaccination) assessed
for ART-naïve cohort.
b Change in ART on day 185 due to toxicity.
c Change in ART on day 221, reason unknown.
d ART initiated on day 371 due to viral load increase.
Fig. 2. Change in viral load from baseline in ART-naïve subjects (TVC). Baseline is the ﬁrst vaccination for each subject; change is expressed by difference in viral load (each
value-baseline) according to number of days after ﬁrst vaccination; lines link the medians at each time point.
Fig. 3. Association between viral load and the frequency of F4-speciﬁc CD40L+CD4+ T-cells expressing at least IL-2 at two weeks post-dose 2 in the ART-naïve cohort (TVC).
Each dot corresponds to data for a given subject.
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RT-experienced subjects, in whom an increased HIV-1-speciﬁc
D4+ T-cell response was still detected at month 12 which was
ost evident against the RT antigen. The observed lower response
n ART-naïve subjects could be explained by the immunosup-
ressive effects of HIV-1 viraemia and direct killing of activated
IV-1-speciﬁc CD4+ T-cells by HIV-1. However, it is remarkable
hat F4/AS01 actually augmented the HIV-1-speciﬁc CD4+ T-cell
esponse in ART-naïve subjects despite ongoing viraemia.
In  keeping with previous ﬁndings in healthy HIV-1-seronegative
olunteers [8], vaccine-induced CD4+ T-cells expressed CD40L and
roduced IL-2 alone or in combination with TNF- and/or IFN-.
his polyfunctional cytokine coexpression proﬁle was  maintained
p to month 12. CD4+ T-cells producing multiple cytokines are con-
idered functionally superior to those producing single cytokines
23] and their association with LTNP in HIV-1 infection is well-
stablished [24–26]. Higher levels of IL-2+ or IL-2+ IFN-+ CD4+
-cells are found in individuals with non-progressing HIV-1 dis-
ase and low viral load [24,26,27]. IL-2+ CD4+ T-cells (memory
henotype) have also been shown to have a protective potential
n HIV-1 infection [28]. CD4+ T-cells proliferate in response to HIV-
 antigens in non-progressive HIV-1 infection, whereas CD4+ T-cell
roliferation is weak or even absent in viremic patients, with IL2 an
mportant cytokine implicated in the proliferation [24]. In another
ecent study, subjects who spontaneously control an HIV-1 infec-
ion were found to display polyfunctional CD4+ T-cell responses
f similar magnitude and quality as those induced by F4/AS01 in
ealthy volunteers [29].
Viral  load remained suppressed in ART-experienced subjects
ver the 12 months of follow-up. In ART-naïve subjects, the
bserved relationship between the magnitude of the F4 CD4+ T-
ell response and the change in viral load from baseline two weeks
ost-dose 2 raised the possibility that CD4+ T-cells play a role in
he control of viraemia in HIV-1 infection.
The lack of impact of F4/AS01 to induce de novo HIV-1-speciﬁc
D8+ T-cell responses in this study is not unexpected. CD8+ T-
ell responses were not seen with the F4/AS01 vaccine in healthy
IV-1-seronegative volunteers [8], and have rarely been observed
ith other candidate vaccines consisting of a protein antigen
ormulated in an adjuvant system (e.g. HBsAg, RTS,S, Mtb72)
20–22], as this approach favours HLA-class II mediated antigen
resentation. Additionally, in this study, the failure to observe a
estoration/improvement of the CD8+ T-cell functionalities present
rior to vaccination could be explained by the high and variable
evels of these pre-existing CD8+ T-cells in most subjects, by the
imitations of the assay used to assess these responses, as well as
y the low number of subjects studied. Although no additional anal-
ses were possible to further characterise the functional properties
f the CD8+ T-cell response (such as proliferation or viral inhibition
ssay), due to the limitation of available PBMC, it is possible that the
rotein-based approach investigated in this study was  truly inef-
ective at inducing de novo nor helping pre-existing CD8+ T cells.
urthermore, although it is generally accepted that HIV-1-speciﬁc
D8+ T-cells are important for the control of HIV-1 viraemia, other
ell-mediated immune responses may  also be involved. Indeed,
vidence is increasing to support a role for cytolytic CD4+ T-cell
esponses and natural killer cells in the control of viral replication
n HIV-1 infection [30–35].
.  Conclusions
F4/AS01 appeared immunogenic with a clinically acceptable
afety proﬁle in both ART-experienced and ART-naïve subjects.
n ART-naïve subjects, vaccination was followed by a transient
eduction in viral load from baseline which coincided with higher
olyfunctional CD4+ T-cell responses. These results supported the (2014) 2657–2665
design of a conﬁrmatory study in more HIV-1-infected patients
(NCT01218113) to investigate further the antiviral potential of
F4/AS01 in the absence of antiretroviral treatment.
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